Wall Street Experts
ver. ZuMIgo(08/25)
Prognozy (mln) dla Tasly Pharmaceutical Group Co., Ltd
| Okres |
2023-12-31 |
2024-12-31 |
2025-12-31 |
2026-12-31 |
| Przychód (średnia) |
8,637.98 |
9,078.36 |
9,942.62 |
10,174.21 |
| Przychód Δ r/r |
0.00% |
5.10% |
9.52% |
2.33% |
| Przychód (min) |
8,566.08 |
9,012.42 |
9,792.11 |
10,059.21 |
| Przychód (max) |
8,721.65 |
9,173.23 |
10,232.03 |
10,377.92 |
| EBITDA (średnia) |
2,044.50 |
2,148.73 |
2,353.29 |
2,408.10 |
| EBIT (średnia) |
1,495.44 |
1,571.68 |
1,721.31 |
1,761.40 |
| EBIT % |
17.31% |
17.31% |
17.31% |
17.31% |
| Zysk netto (średni) |
1,101.70 |
1,212.45 |
1,430.28 |
1,493.90 |
| Zysk netto % |
12.75% |
13.36% |
14.39% |
14.68% |
| EPS (średnia) |
0.74 |
0.81 |
0.95 |
1.00 |
| Liczba analityków (Przychody) |
4 |
6 |
7 |
6 |
| Liczba analityków (EPS) |
4 |
6 |
6 |
6 |
| symbol |
600535.SS |
600535.SS |
600535.SS |
600535.SS |